Showing 15 posts of 241 posts found.


Merck shares data from phase 3 trial for breast cancer treatment

August 1, 2023
Research and Development MSD, Merck, Oncology, breast cancer, keytruda

Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

June 9, 2023
Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …


MSD announce new data from advanced renal cell carcinoma trial

June 8, 2021
Manufacturing and Production MSD, rcc

Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) plus Lenvima (lenvatinib), and Lenvima …

NICE rejects Merck Serono’s Bavencio for urothelial cancer

May 10, 2021
Sales and Marketing MSD, Merck, NHS, NICE, cancer treatment, pharma, pharma news

The use of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy is not recommended by …

Merck kidney and uterus cancer treatments granted priority review by FDA

May 7, 2021
Medical Communications FDA, MSD, Merck, cancer treatment, kidney cancer treatment, pharma, pharma news, uterus cancer treatment

The FDA has granted priority review for Merck (MSD) and Eisai’s application for two new approvals for the combination of …

Merck cease development of $425 million COVID-19 treatment

April 16, 2021
Medical Communications COVID-19, MSD, Merck, covid-19 treatment, pharma, pharma news

Merck (MSD) have ended the development of their MK-7110 drug for the treatment of hospitalised patients with COVID-19.

NHS agrees on MSD interim colorectal cancer treatment

March 25, 2021
COVID-19, Cancer, MSD, NHS

MSD has announced a provisional agreement with the NHS to make KEYTRUDA (pembrolizumab) available for eligible patients with metastatic MSI-H/dMMR …

AstraZeneca & MSD ovarian cancer drug combination approved by NICE

March 19, 2021
Medical Communications AstraZeneca, MSD, NICE, oncology

A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …


Gilead and MSD partner to develop and commercialise two-drug HIV regimen

March 16, 2021
Manufacturing and Production Gilead, HIV, MSD

Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …


MSD acquires Pandion Therapeutics in $1.85bn deal

February 26, 2021
Medical Communications MSD, Pandion

MSD, known as Merck in the United States and Canada, has announced that it will acquire clinical-stage biotechnology company Pandion …


AstraZeneca and MSD’s Lynparza crosses superiority boundary for invasive disease-free survival

February 17, 2021
Research and Development AstraZeneca, Cancer, MSD

The OlympiA Phase III trial for AstraZeneca and MSD’s cancer drug Lynparza will move to early primary analysis and reporting, …

NICE recommends MSD’s Keytruda in combination with chemotherapy for lung cancer

February 4, 2021
Cancer, MSD

NICE has recommended MSD’s Keytruda (pembrolizumab) with pemetrexed and platinum chemotherapy (pembrolizumab combination) as a first-line option for untreated, metastatic, …


Combination of Keytruda and Yervoy does not improve cancer survival, MSD trial finds

February 2, 2021
Manufacturing and Production Cancer, MSD

A new trial by Merck – known as MSD outside of North America – has found that their lung cancer …


MSD’s cancer therapy KEYTRUDA gets EU approval

January 26, 2021
Manufacturing and Production Cancer, MSD

MSD, known as Merck in the US and Canada, has received approval from the European Commission (EC) for its anti-PD-1 …


MSD discontinues development of COVID-19 vaccines

January 26, 2021
Manufacturing and Production MSD, Merck

Merck, known as MSD outside of the US and Canada, has announced that the company is discontinuing development of its …

Latest content